Aspira Women Health : Management Change/Compensation - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 20, 2024, Aspira Women's Health Inc. (the "Company") entered into an amendment (the "Hombeck Amendment") to its employment agreement with Torsten Hombeck, the Company's Chief Financial Officer (as amended by the Hombeck Amendment, the "Hombeck Agreement"). The Hombeck Amendment commenced on March 13, 2024 and shall continue until March 31, 2025 (the "Hombeck Amendment Term"). Pursuant to the terms of the Hombeck Amendment, Mr. Hombeck will be eligible for a bonus of up to $50,000 upon the closing of one or more equity or debt financing transactions that result in total aggregate net proceeds to the Company of $3,000,000 or more during the Hombeck Amendment Term. The bonus will increase to $100,000 upon the aggregate closing of one or more equity, debt or other financing transactions that result in total net proceeds to the Company of $5,000,000 or more during the Hombeck Amendment Term.

Mr. Hombeck is eligible for an additional cash bonus, which amount is to be determined by the Compensation Committee of the Board of Directors, for performance related to the closing of any additional non-dilutivecash generating transactions entered into during the Hombeck Amendment Term. Any such pro rata bonuses will be payable to Mr. Hombeck within 30 days of receipt of proceeds by the Company (but in any event no later than March 31, 2025).

The foregoing description of the Hombeck Amendment is qualified in its entirety by reference to the full text of the Hombeck Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.